Difference between revisions of "Avatrombopag (Doptelet)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
m (Also known as)
Line 21: Line 21:
  
 
[[Category:Immune thrombocytopenia (ITP) medications]]
 
[[Category:Immune thrombocytopenia (ITP) medications]]
 +
[[Category:Thrombocytopenia in liver disease medications]]
  
 
[[Category:FDA approved in 2018]]
 
[[Category:FDA approved in 2018]]

Revision as of 22:24, 4 August 2018

Mechanism of action

Thrombopoietin receptor agonist

Diseases for which it is used

  1. Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed

History of changes in FDA indication

Also known as

  • Code names: E5501, YM477, AKR 501
  • Brand name: Doptelet